BriaCell Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Selling, General & Admin	6.55	6.39	6.57	8.51	7.58	4.96
Research & Development	23.82	20.81	26.76	14.76	7.71	2.02
Operating Expenses	30.37	27.2	33.33	23.27	15.29	6.98
Operating Income	-30.37	-27.2	-33.33	-23.27	-15.29	-6.98
Interest Expense	-0.04	-0.04	-	-	-0	-0.08
Interest & Investment Income	0.16	0.12	0.29	0.89	0.14	0
Earnings From Equity Investments	-0.2	-0.22	-0.11	-	-	-
Currency Exchange Gain (Loss)	-0	-0.02	-0.03	-0.04	-0.03	-2.18
Other Non Operating Income (Expenses)	1.31	0.76	28.24	2.12	-11.65	-4.45
EBT Excluding Unusual Items	-29.15	-26.61	-4.93	-20.3	-26.84	-13.67
Gain (Loss) on Sale of Investments	0.15	0.06	-	-	-	-
Other Unusual Items	-	-	-	-	-	-0.14
Pretax Income	-29.01	-26.56	-4.93	-20.3	-26.84	-13.82
Earnings From Continuing Operations	-29.01	-26.56	-4.93	-20.3	-26.84	-13.82
Minority Interest in Earnings	0.3	0.24	0.14	-	-	-
Net Income	-28.71	-26.31	-4.79	-20.3	-26.84	-13.82
Net Income to Common	-28.71	-26.31	-4.79	-20.3	-26.84	-13.82
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	566.61%	285.70%	5.35%	0.81%	242.82%	-
EPS (Basic)	-33.79	-62.19	-43.68	-194.97	-259.83	-458.54
EPS (Diluted)	-33.79	-62.19	-43.68	-194.97	-259.83	-458.54
Free Cash Flow	-28.92	-28.17	-24.58	-23.74	-12.48	-7.75
Free Cash Flow Per Share	-34.04	-66.58	-224.09	-228.03	-120.86	-257.22
EBITDA	-30.27	-27.1	-33.25	-23.26	-15.27	-6.96
D&A For EBITDA	0.11	0.11	0.08	0.02	0.02	0.02
EBIT	-30.37	-27.2	-33.33	-23.27	-15.29	-6.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.